<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77232">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01892345</url>
  </required_header>
  <id_info>
    <org_study_id>ECU-NMO-301</org_study_id>
    <nct_id>NCT01892345</nct_id>
  </id_info>
  <brief_title>A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the efficacy and safety of eculizumab
      treatment as compared to placebo in relapsing NMO patients using a time to first relapse
      study design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>from baseline to end of study</time_frame>
    <safety_issue>No</safety_issue>
    <description>On-trial NMO Relapse, as defined by the protocol.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall safety and tolerability of eculizumab</measure>
    <time_frame>from baseline to end of study</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events, vital signs and laboratory assessments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Neuromyelitis Optica</condition>
  <condition>Neuromyelitis Optica Spectrum Disorder</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Eculizumab IV Infusion</description>
    <arm_group_label>eculizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female patients ≥ 18 years old

          2. Diagnosis of NMO or NMO spectrum disorder

          3. All patients must be NMO-IgG seropositive

          4. Clinical evidence of at least 2 relapses in last 12 months or 3 relapses in the last
             24 months (with at least 1 relapse in the 12 months prior to the Screening)

          5. EDSS score ≤7

          6. Immunosuppressive therapy is allowed provided patients have been on a stable
             maintenance dose prior to the Screening and remain on a stable dose for the duration
             of the study

        Key Exclusion Criteria:

          1. Use of rituximab within 3 months prior to screening

          2. Use of mitoxantrone within 3 months prior to screening

          3. Use of IVIg within 3 weeks prior to screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals (Sponsor)</last_name>
    <email>clinicaltrials@alxn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Research Center of Southern California</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10466</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexion Pharmaceuticals</last_name>
      <email>clinicaltrials@alxn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O'Toole O, Wingerchuk DM. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013 Jun;12(6):554-62. doi: 10.1016/S1474-4422(13)70076-0. Epub 2013 Apr 26.</citation>
    <PMID>23623397</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>June 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neuromyelitis Optica</keyword>
  <keyword>Neuromyelitis Optica Spectrum Disorder</keyword>
  <keyword>Devic's disease, Transverse Myelitis</keyword>
  <keyword>Optic Neuritis</keyword>
  <keyword>relapse</keyword>
  <keyword>eculizumab</keyword>
  <keyword>soliris</keyword>
  <keyword>NMO-IgG</keyword>
  <keyword>CNS Autoimmune Disorders</keyword>
  <keyword>Demyelinating Disorders</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
